ProCE Banner Activity


IBD Management in Primary Care: Keys to Successful Diagnosis, Treatment, and Ongoing Care

PCE On Demand Live Presentation

Inflammatory bowel disease (IBD) affects approximately 1.6 million people in the United States, including 80,000 children and adolescents. Diagnostic difficulties and treatment delays put patients at risk for poorer overall patient outcomes and increased risk of hospitalization and surgery. The advent of biologic and small-molecule targeted therapies has greatly improved outcomes for pediatric and adult patients with IBD, particularly when initiated early and optimized to reach treatment targets. It is imperative that clinicians practicing in primary care are equipped to recognize the signs of IBD to place timely referrals for evaluations and diagnosis. In addition, they are integral members of the collaborative IBD care team in managing extraintestinal manifestations, addressing disparities in care, optimizing health maintenance, and monitoring the efficacy and safety of therapies.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: September 30, 2022

Expiration: September 29, 2023



Dermot McGovern

Dermot McGovern, MD, PhD, FRCP

Professor of Medicine
Translational Research in the Inflammatory Bowel
and Immunobiology Research Institute
Cedars-Sinai Medical Center
Los Angeles, California

Susan Tiso

Susan Tiso, DNP, FNP-BC

Consultant; Retired Clinical Professor
Sue & Bill Gross School of Nursing
Family Nurse Practitioner
Department of Family Medicine
University of California, Irvine
Irvine, California


This activity is supported by an educational grant from Bristol-Myers Squibb.


Bristol Myers Squibb

Target Audience

NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify signs and symptoms of IBD in both pediatric and adult patients to allow for early diagnosis and treatment

  • Summarize the impact of biologic therapies and small-molecule inhibitors on treatment goals for IBD

  • Outline expanded therapeutic indications and new and emerging treatment options for pediatric and adult IBD

  • Implement recommended strategies for the long-term management of patients with IBD


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dermot McGovern, MD, PhD: consultant/advisor/speaker: Gilead, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Takeda; stock options: Prometheus Biosciences.

Susan Tiso, DNP, FNP-BC has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Dermot McGovern, MD, PhD as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: September 30, 2022
Expiration date: September 29, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Susan Tiso, DNP, FNP-BC, University of California, Irvine, Irvine, California

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 29, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Tracey M. Piparo, PA-C, RWJ Barnabas Health, New Brunswick, New Jersey

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.